Melane Sampson, Author at BioTuesdays

Developments

Adaptive partners with NeoGenomics to advance blood cancer monitoring

Adaptive Biotechnologies (NASDAQ:ADPT) and NeoGenomics (NASDAQ:NEO) have announced a multi-year exclusive collaboration aimed at advancing minimal residual disease (MRD) monitoring options for patients with select blood...

January 14, 2025

Executive Moves

Terence Tan joins William Blair’s Biopharma Investment Banking Group

William Blair, a global investment firm, has announced the addition of Terence Tan as managing director in its healthcare investment banking team. In this role, Mr. Tan will focus on delivering comprehensive advisory...

January 14, 2025

Feature

ROMTech advancing postoperative rehabilitation with unparalleled patient outcomes

Closely-held ROMTech is combining cutting-edge innovation with advanced telemedicine technology, transforming rehabilitation, diagnostics, facilitating seamless remote patient-physician connections for at-home...

January 14, 2025

Developments

Arrivo unveils positive study results on SP-624’s impact on depression and cognition

Closely held Arrivo BioVentures has announced promising results from its study evaluating SP-624’s novel epigenetic mechanism of action on neurological pathways. According to the company, the findings provide insights...

January 10, 2025

Developments

FDA grants additional FTD to Mersana’s XMT-1660 for breast cancer

Mersana Therapeutics (NASDAQ:MRSN) has announced that the FDA has granted an additional fast track designation (FTD) to its emiltatug ledadotin (XMT-1660) for the treatment of advanced or metastatic breast cancer. The...

January 10, 2025

Developments

Genenta strengthens pact with CDMO to enhance production

Genenta Science (NASDAQ:GNTA) announced that it has amended its development and master services agreement with contract development and manufacturing organization (CDMO) AGC Biologics to bolster production capabilities...

January 10, 2025

Developments

Inspira responds to China’s recent hMPV outbreak; prepares to ramp up production

Inspira Technologies (NASDAQ:IINN) has announced its preparations for a possible increase in production of its INSPIRA ART100 device to address the growing demand for advanced respiratory care technologies following the...

January 10, 2025

Developments

Onco-Innovations’ technology aims to transform cancer treatments

Onco-Innovations (CSE:ONCO; FRANKFURT:W1H; WKN:A3EKSZ) has announced that its exclusively-licensed, patented polynucleotide kinase 3’-phosphates (PNKP) inhibitors technology holds the potential to significantly enhance...

January 9, 2025

Executive Moves

Dr. Elena Ratner joins Eterna’s BOD

Eterna Therapeutics (NASDAQ:ERNA) has announced the appointment of Elena Ratner, MD, MBA, to its board of directors. The company states that Dr. Ratner will spearhead the strategic direction of Eterna’s efforts to...

January 9, 2025

Developments

MOBILion spotlights 100th peer-reviewed publication featuring its separations technology platform

Closely held MOBILion Systems has announced that, as of December 24, 2024, its foundational Structures for Lossless Ion Manipulation (SLIM) platform technology has been highlighted in 100 peer-reviewed publications in...

January 8, 2025

Author - Melane Sampson

Adaptive partners with NeoGenomics to advance blood cancer monitoring

Terence Tan joins William Blair’s Biopharma Investment Banking Group

ROMTech advancing postoperative rehabilitation with unparalleled patient outcomes

Arrivo unveils positive study results on SP-624’s impact on depression and cognition

FDA grants additional FTD to Mersana’s XMT-1660 for breast cancer

Genenta strengthens pact with CDMO to enhance production

Inspira responds to China’s recent hMPV outbreak; prepares to ramp up production

Onco-Innovations’ technology aims to transform cancer treatments

Dr. Elena Ratner joins Eterna’s BOD

MOBILion spotlights 100th peer-reviewed publication featuring its separations technology platform

General

More